Global Cannabis Applications Corp. (“GCAC” or the “Company”) (CSE:APP, FSE:2FA, OTCQB: FUAPF), a leading developer of innovative data technologies for the cannabis industry, is pleased to announce that it has entered into a strategic partnership with SciCann Therapeutics, a pharmaceutical company based in Israel and Canada which is developing innovative cannabinoid based pharmaceuticals and therapies for a wide range of debilitating ailments. SciCann was founded and is led by Dr. Zohar Koren, a world leading scientist in the study of novel and disruptive therapeutic products based on cannabinoids.
“I am impressed with the direction of GCAC’s medical cannabis data focus and, as practitioner in the medical cannabis field, I see its long over due value,” said Dr. Zohar Koren, CEO of SciCann Therapeutics. “By combining our scientific research and clinical data with GCAC technologies, we can deliver superior data outputs that can be used to provide better medical cannabis products for patients around the world. The synergistic value and impact of combining our data and clinical research tools together with GCAC’s artificial intelligence and blockchain environment is enormous.”
“I am delighted to be collaborating with Dr. Koren and SciCann Therapeutics with a history of conducting important clinical studies on cannabinoids,” said Brad Moore, CEO of GCAC. “SciCann works on canna driven therapeutic products in the fields of oncology, pain management, neurodegenerative diseases and inflammatory disorders, and will work in synergy with GCAC’s Pain to Strain model. Our recent expansion into Lithuania’s blockchain community is reflective of our continued commitment to implement real technology based solutions related to medical cannabis. We believe that the value of the partnership with SciCann will be extremely beneficial to future development projects with licensed producers, canna product developers and insurers, greatly adding to our revenue objectives.”
Dr. Koren holds a Ph.D. and M.Sc. in Computational Biology, both Magna Cum Laude, from the University of Haifa, and a B.Sc. in Mathematics, Physics and Biology from the Hebrew University in Jerusalem. In 2012, he co-founded Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a company focused on harnessing the therapeutic properties of natural cannabinoid compounds, and served as Chief Executive Officer and Director. He served as VP Business Development of Mor Research Applications – the commercial arm of Clalit Healthcare services, Israel’s largest health organization that operates a network of 14 hospitals and has a annual turnover of over $6 billion. He has held senior executive roles at several pharma companies including Aposense and Talent Biotechs. Dr. Koren has also provided strategic consulting services for several leading Israeli venture capital firms specific to the pharmaceutical and medical device arena.
About Global Cannabis Applications Corp.
Global Cannabis Applications Corp. is a global leader in designing, developing, marketing, and acquiring innovative data technologies for the cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, reg tech, smart databases, blockchain and digital reward tokens, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in medical cannabis. Managed by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.
For more information about the Company, please visit online at, or review its profiles and on the Canadian Securities Exchange’s website (
To schedule an interview, please contact:
Bradley Moore
Chief Executive Officer
Telephone: 514-561-9091
For more information, please contact:
Corporate Communications
Telephone: 1.855.269.9554
Forward-Looking Information
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.
Click here to connect with Global Cannabis Applications Corp. (CSE:APP, FSE:2FA, OTCQB: FUAPF) for an Investor Presentation


Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Bart Oates Esq., President of the NFL Alumni Association, to its Advisory Board.

Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has submitted its dossier to the United Kingdom’s Regulatory Food Safety Agency (the “FSA”).

This press release features multimedia. View the full release here:

Keep reading... Show less